Jun 26, 2026 · 6 min
Onsemi targets Synaptics as chip stocks swing
Synaptics Rises, Lumentum Falls, Acadia Pharma Jumps on Positive CHMP Drug Opinion
The episode connects a $6.2 billion semiconductor acquisition with wider sector volatility and a sharp regulatory-driven move in Acadia Pharmaceuticals.
- 1Onsemi agreed to acquire Synaptics in an all-stock deal valued at approximately $6.2 billion.
- 2SanDisk’s decline reflects broader volatility across semiconductor stocks after recent Micron earnings.
- 3Acadia Pharmaceuticals surged after a positive European regulatory opinion for its Rett syndrome drug.
Don't miss
Ellie Lipschultz breaks down how the Onsemi-Synaptics transaction creates an arbitrage trade amid volatile semiconductor markets.
The brief
Onsemi’s agreement to acquire Synaptics for approximately $6.2 billion in stock sets the episode’s central market event and raises the question of how investors price the deal.
Ellie Lipschultz explains the merger’s stock movements and the arbitrage trade, while the report highlights veteran technology M&A banker Frank Quattrone’s involvement.
The focus widens from one transaction to semiconductor-sector volatility, with SanDisk falling as the Philadelphia Semiconductor Index reacts to recent Micron earnings.
Acadia Pharmaceuticals provides a contrasting market move: its shares jumped after a positive European regulatory opinion for its Rett syndrome drug.
Taken together, the episode shows how deal mechanics, earnings-driven sector sentiment, and regulatory news can pull stocks in sharply different directions.
What was said on this episode
4 statements · 4 positive
The acquisition expands On Semiconductor's total addressable market beyond data centers.
“this does expand their TAM as opposed to just really diving deeper into data centers”
Listen at 1:45
The Philadelphia Semiconductor Index remains up approximately 91% year to date.
“the SOX is up, I don't know, 91% year to date still”
Listen at 2:49
The European CHMP gave Acadia's Rett syndrome drug a positive opinion.
“gave a positive opinion for its drug to treat symptoms of Rett syndrome”
Listen at 3:18
The positive CHMP opinion improves the drug's potential for European Union sales.
“positive update obviously as it relates to the potential for sales of this drug in the European Union”
Listen at 3:40
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
Frank Quattrone
SanDiskListen to the full episode and explore every guest, topic, and moment on PodLume.